SEC Tracker
Get the app

Rani Therapeutics Holdings RANI

Rani Therapeutics reports Q3 2026 results and FDA ETP acceptance

Rani Therapeutics Holdings (RANI) filed an 8-K with the SEC on Nov 9, 2026, 5:00 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities of $45.3 million as of September 30, 2026
  2. Accepted into FDA's Emerging Technology Program in October 2026
  3. Net loss of $8.8 million for the three months ended September 30, 2026
  4. Expect to fund operations through end of 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Rani Therapeutics Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.